Cancer Family
Musculoskeletal Neoplasm
CI-CAN-00000278Explore in graph →
Non-malignant212 active trials5 approved drugs54 evidence items
- NCIt
- C166354
Loading cancer entity…
Cancer Family
CI-CAN-00000278Explore in graph →
Clinical trials
1,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02923778 | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 2 | Sep 25, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH |
| 2 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | active not recruiting | Phase 1 / Phase 2 | 62 | Massachusetts General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT01267955 | Vismodegib in Treating Patients With Advanced Chondrosarcomas | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03851614 | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors(DAPPER) | active not recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT04458922 | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04554914 | A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | active not recruiting | Phase 2 | 190 | Pierre Fabre MedicamentINDUSTRY | 7 | Jul 31, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT00508443 | Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS) | active not recruiting | Phase 1 / Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04624178 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT06416085 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer | active not recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00840047 | Methionine PET/CT Studies In Patients With Cancer | active not recruiting | Phase 2 | 503 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | active not recruiting | Phase 2 | 115 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04200443 | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | active not recruiting | Phase 2 | 96 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT00186992 | Radiation Therapy to Treat Musculoskeletal Tumors | active not recruiting | Phase 2 | 202 | St. Jude Children's Research HospitalOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02880319 | Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone | active not recruiting | Phase 2 | 150 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04658771 | MR-HIFU Treatment of Painful Osteoid Osteoma | active not recruiting | Phase 2 | 30 | Children's National Research InstituteOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04974008 | Osteosarcoma Maintenance Therapy With OST31-164(OST-164-01) | active not recruiting | Phase 2 | 39 | Emerald Clinical Inc.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials